Search

Displaying results 3781 - 3790 of 7284 in total
  1. Target

    Succinate dehydrogenase

    go.drugbank.com/bio_entities/BE0010253
    EnzymeTargetHumans

    Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed … Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to

    Synonyms: Flavoprotein subunit of complex II, Iron-sulfur subunit of complex II
  2. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … [A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer.

  3. Drug

    Tamoxifen

    go.drugbank.com/drugs/DB00675
    ApprovedInvestigational

    [A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799] … Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.

    International brands: Nolvadex-DCategories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  4. Drug

    Bucainide

    go.drugbank.com/drugs/DB20650
    Experimental

    Bucainide has a monoisotopic molecular weight of 329.28 Da. … Bucainide is a small molecule drug. The usage of the INN stem '-cain-' in the name indicates that Bucainide is a class I antiarrhythmic, procainamide and lidocaine derivative.

  5. Drug

    Methylnaltrexone

    go.drugbank.com/drugs/DB06800
    ApprovedInvestigational

    It is also a weak CYP2D6 inhibitor. FDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.

  6. Drug

    Cinuperone

    go.drugbank.com/drugs/DB19498
    Experimental

    Cinuperone has a monoisotopic molecular weight of 377.19 Da. … Cinuperone is a small molecule drug. The usage of the INN stem '-perone' in the name indicates that Cinuperone is a tranquillizer, neuroleptic, 4'-fluoro-4-piperidinobutyrophenone derivative.

  7. Drug

    Declenperone

    go.drugbank.com/drugs/DB19700
    Experimental

    Declenperone has a monoisotopic molecular weight of 381.19 Da. … Declenperone is a small molecule drug. The usage of the INN stem '-perone' in the name indicates that Declenperone is a tranquillizer, neuroleptic, 4'-fluoro-4-piperidinobutyrophenone derivative.

  8. Drug

    Dasantafil

    go.drugbank.com/drugs/DB19918
    Experimental

    Dasantafil has a monoisotopic molecular weight of 521.13 Da. … Dasantafil is a small molecule drug. The usage of the INN stem '-afil' in the name indicates that Dasantafil is a inhibitor of phosphodiesterase PDE5 with vasodilator action.

  9. Drug

    Embusartan

    go.drugbank.com/drugs/DB19949
    Experimental

    Embusartan has a monoisotopic molecular weight of 461.19 Da. … Embusartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

  10. Drug

    Tauromustine

    go.drugbank.com/drugs/DB19978
    Experimental

    Tauromustine has a monoisotopic molecular weight of 286.05 Da. … Tauromustine is a small molecule drug. The usage of the INN stem '-mustine' in the name indicates that Tauromustine is a antineoplastic, alkylating agent, (β-chloroethyl) amine derivative.